Aim: The aim of this study was to investigate prognostic factors for survival in patients with advanced NSCLC who receiving second-line chemotherapy. Methods: We retrospectively reviewed data of 116 patients with NSCL...Aim: The aim of this study was to investigate prognostic factors for survival in patients with advanced NSCLC who receiving second-line chemotherapy. Methods: We retrospectively reviewed data of 116 patients with NSCLC receiving second-line treatments from October 2010 to December 2012 in Clinic for Lung Diseases of Clinical center Nis, Department for Pulmonary Oncology. Thirteen potential prognostic factors were chosen for analysis. Univariate analysis was conducted to identify prognostic factors associated with progression free survival and overall survival. Multivariate analysis included the prognostic significance factors in univariate analysis. Results: The univariate analysis for progression free survival (PFS) and overall survival (OS) was identified to have prognostic significance: performance status, smoking, weight loss, comorbidity, number of meta localization, first-line chemotherapy regimen and response to first-line chemotherapy. Nevertheless, multivariate Cox prortional hazard regression analysis showed that performance status (PFS: p = 0.000, OS: p = 0.000) weight loss ≥ 5% (PFS: p = 0.000, OS: p = 0.002), comorbidity (PFS: p = 0.001, OS: p = 0.012) and four places of meta localization (PFS: p = 0.021, OS: p = 0.021) were considered independent prognostic factors for both, progression free survival and overall survival. Conclusion: Performance status, weight loss ≥ 5%, comorbidity and higher number of meta localization were identified as prognostic factors for survival in advanced NSCLC patients receiving second-line chemotherapy treatment. These findings may help pretreatment prediction of survival and may facilitate in the future integration new agents into second-line treatment.展开更多
目的系统评价肌肉减少症对肺癌患者生存期的影响。方法通过中国知网、万方数据库、维普、中国生物医学文献数据库、PubMed、Embase、Web of Science、Cochrane Library、MEDLINE数据库检索自建库至2022年12月31日关于肌肉减少症对肺癌...目的系统评价肌肉减少症对肺癌患者生存期的影响。方法通过中国知网、万方数据库、维普、中国生物医学文献数据库、PubMed、Embase、Web of Science、Cochrane Library、MEDLINE数据库检索自建库至2022年12月31日关于肌肉减少症对肺癌患者生存期影响的相关文献。采用RevMan 5.3及Stata 15.0软件进行分析,主要结局指标包括总生存期(OS)和无进展生存期(PFS)。结果最终纳入14篇队列研究文献,共1923例患者。Meta分析结果显示,肌肉减少症是肺癌患者OS的危险因素(HR=1.47,95%CI:1.20~1.81,P=0.0003),不是肺癌患者PFS的影响因素(HR=0.88,95%CI:0.39~1.96,P=0.75)。根据样本量进行亚组分析结果显示,肌肉减少症是肺癌患者OS的危险因素(P﹤0.05);根据肿瘤类型进行亚组分析结果显示,肌肉减少症是非小细胞肺癌(NSCLC)患者OS的危险因素(P﹤0.05);根据地区进行亚组分析结果显示,在欧美国家中,肌肉减少症是肺癌患者OS的危险因素(P﹤0.05)。结论肌肉减少症是肺癌患者OS的危险因素,肌肉减少症可以作为预测肺癌患者OS的指标,而对PFS的影响未来仍需更多研究进一步证实。展开更多
文摘Aim: The aim of this study was to investigate prognostic factors for survival in patients with advanced NSCLC who receiving second-line chemotherapy. Methods: We retrospectively reviewed data of 116 patients with NSCLC receiving second-line treatments from October 2010 to December 2012 in Clinic for Lung Diseases of Clinical center Nis, Department for Pulmonary Oncology. Thirteen potential prognostic factors were chosen for analysis. Univariate analysis was conducted to identify prognostic factors associated with progression free survival and overall survival. Multivariate analysis included the prognostic significance factors in univariate analysis. Results: The univariate analysis for progression free survival (PFS) and overall survival (OS) was identified to have prognostic significance: performance status, smoking, weight loss, comorbidity, number of meta localization, first-line chemotherapy regimen and response to first-line chemotherapy. Nevertheless, multivariate Cox prortional hazard regression analysis showed that performance status (PFS: p = 0.000, OS: p = 0.000) weight loss ≥ 5% (PFS: p = 0.000, OS: p = 0.002), comorbidity (PFS: p = 0.001, OS: p = 0.012) and four places of meta localization (PFS: p = 0.021, OS: p = 0.021) were considered independent prognostic factors for both, progression free survival and overall survival. Conclusion: Performance status, weight loss ≥ 5%, comorbidity and higher number of meta localization were identified as prognostic factors for survival in advanced NSCLC patients receiving second-line chemotherapy treatment. These findings may help pretreatment prediction of survival and may facilitate in the future integration new agents into second-line treatment.